| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
Oleuroside targets mitochondria and oxidative stress pathways. It prevents mitochondrial dysfunction by protecting against oxidative damage and maintaining mitochondrial function. The compound modulates inflammatory pathways and protects against lipid peroxidation. Its antioxidant activity involves scavenging free radicals and reducing oxidative stress. Its anti-inflammatory activity involves the inhibition of pro-inflammatory mediators. The compound's antimicrobial activity is attributed to its ability to disrupt microbial membranes.
|
|---|---|
| ln Vitro |
In SY5Y-APP695 cells, oleeuroside dramatically raises basal ATP levels [1].
In vitro studies demonstrate that Oleuroside significantly increases basal ATP levels in SYSY-APP695 cells. The compound exhibits antioxidant activity by scavenging free radicals and protecting against lipid peroxidation. It modulates inflammatory pathways by reducing the production of pro-inflammatory cytokines. Its antimicrobial activity has been demonstrated against various pathogens. The compound's neuroprotective effects are attributed to its ability to prevent mitochondrial dysfunction. |
| ln Vivo |
In vivo activity of Oleuroside has not been extensively characterized in the available literature. As a bioactive natural product with antioxidant, anti-inflammatory, and neuroprotective properties, the compound has potential for cardiovascular protection and the treatment of neurodegenerative diseases. However, detailed in vivo efficacy data are not extensively reported. The compound is primarily used as a research tool.
|
| Enzyme Assay |
In vitro assays for Oleuroside involve measuring its antioxidant, anti-inflammatory, and mitochondrial protective activities. Antioxidant activity is assessed using DPPH, ABTS, or ORAC assays. Anti-inflammatory activity is evaluated in cell-based assays by measuring the inhibition of pro-inflammatory cytokine production in stimulated macrophages. Mitochondrial function is assessed by measuring ATP levels, mitochondrial membrane potential, and oxygen consumption rate in neuronal cell models.
|
| Cell Assay |
Cellular assays for Oleuroside are conducted to evaluate its neuroprotective and anti-inflammatory effects. Neuronal cells (e.g., SYSY-APP695 cells) are treated with the compound, and ATP levels are measured using luciferase-based assays. Mitochondrial function is assessed by measuring mitochondrial membrane potential using fluorescent dyes (e.g., JC-1) and oxygen consumption rate. Inflammatory cytokine production is measured in stimulated immune cells using ELISA. Cell viability is assessed using MTT or similar assays.
|
| Animal Protocol |
In vivo animal studies for Oleuroside are limited. For neuroprotective studies, animal models of Alzheimer's disease or brain aging could be used. Animals would be treated with the compound via oral or intraperitoneal administration at various doses. Cognitive function, oxidative stress markers, and mitochondrial function would be assessed. However, specific in vivo study protocols are not extensively reported.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Oleuroside have not been extensively characterized. The compound has a molecular weight of 540.5 and a molecular formula of C2₅H32O13. It has a density of 1.49+/-0.1 g/cm3 and a solubility of 42 g/L at 25degC. Detailed PK parameters such as half-life, bioavailability, and volume of distribution are not reported in the available literature. The compound is typically stored at -20degC.
|
| Toxicity/Toxicokinetics |
Toxicological data for Oleuroside are limited. The compound is not intended for human therapeutic use and is supplied for research purposes only. In cell-based assays, the compound is generally well-tolerated at concentrations used for activity studies. The compound is derived from natural sources (olives) and is considered to have low toxicity. Standard safety precautions should be followed when handling this compound.
|
| References | |
| Additional Infomation |
Oleuroside is a phenolic secoiridoid from olives with antioxidant, anti-inflammatory, antimicrobial, and neuroprotective properties. It prevents mitochondrial dysfunction in models of Alzheimer's disease and brain aging. The compound significantly increases basal ATP levels in neuronal cells. It is not an FDA-approved drug and has no clinical indications. The compound is available in high purity and is typically stored at -20degC.
|
| Molecular Formula |
C25H32O13
|
|---|---|
| Molecular Weight |
540.5138
|
| Exact Mass |
540.184
|
| CAS # |
116383-31-4
|
| PubChem CID |
14136852
|
| Appearance |
White to off-white solid
|
| LogP |
0
|
| Hydrogen Bond Donor Count |
6
|
| Hydrogen Bond Acceptor Count |
13
|
| Rotatable Bond Count |
12
|
| Heavy Atom Count |
38
|
| Complexity |
847
|
| Defined Atom Stereocenter Count |
8
|
| SMILES |
COC(=O)C1=CO[C@H]([C@@H]([C@@H]1CC(=O)OCCC2=CC(=C(C=C2)O)O)C=C)O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O
|
| InChi Key |
WWKVQWHAWPZZDB-ASNPJKIBSA-N
|
| InChi Code |
InChI=1S/C25H32O13/c1-3-13-14(9-19(29)35-7-6-12-4-5-16(27)17(28)8-12)15(23(33)34-2)11-36-24(13)38-25-22(32)21(31)20(30)18(10-26)37-25/h3-5,8,11,13-14,18,20-22,24-28,30-32H,1,6-7,9-10H2,2H3/t13-,14+,18-,20-,21+,22-,24+,25+/m1/s1
|
| Chemical Name |
methyl (2S,3R,4S)-4-[2-[2-(3,4-dihydroxyphenyl)ethoxy]-2-oxoethyl]-3-ethenyl-2-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,4-dihydro-2H-pyran-5-carboxylate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~50 mg/mL (~92.51 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1.25 mg/mL (2.31 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 1.25 mg/mL (2.31 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 1.25 mg/mL (2.31 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.8501 mL | 9.2505 mL | 18.5010 mL | |
| 5 mM | 0.3700 mL | 1.8501 mL | 3.7002 mL | |
| 10 mM | 0.1850 mL | 0.9251 mL | 1.8501 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
